SynNotch CAR 电路增强实体瘤识别并维持小鼠模型持久抗肿瘤活性
该研究基于合成 Notch(synNotch)CAR 电路改造治疗性 T 细胞,以提高实体瘤识别的特异性与持久抗肿瘤活性。研究鉴定 ALPPL2 为多种实体瘤(含间皮瘤、卵巢癌)的肿瘤特异性抗原,可单独或与 MCAM、间皮素、HER2 组合用于 synNotch CAR 组合抗原电路。在小鼠间皮瘤与卵巢癌模型中,synNotch CAR T 细胞对肿瘤负荷的控制优于组成型表达同一抗原 CAR 的 T 细胞。
要点
- ALPPL2 可作为间皮瘤、卵巢癌等实体瘤的 CAR 治疗靶点
- synNotch 调控的 CAR 表达可避免组成型表达导致的 tonic 信号
- synNotch CAR T 细胞在小鼠模型中维持长效记忆、非耗竭表型
核心结论
- synNotch CAR 电路可提升实体瘤 T 细胞治疗的特异性与持久抗肿瘤活性,ALPPL2 成为多种实体瘤的可行细胞治疗靶点。
研究设计与样本
- 研究在人间皮瘤与卵巢癌小鼠模型中比较 synNotch CAR T 细胞与组成型表达靶向相同抗原 CAR 的 T 细胞。
主要发现
- ALPPL2 在包括间皮瘤和卵巢癌在内的多种实体瘤中作为肿瘤特异性抗原表达。
- 在小鼠间皮瘤和卵巢癌模型中,synNotch CAR T 细胞对肿瘤负荷的控制优于组成型 CAR T 细胞。
- 该优势通过 synNotch 控制 CAR 表达、防止 CAR 介导的 tonic 信号实现,使 T 细胞维持长效记忆与非耗竭表型。
临床怎么用
- 可考虑将 ALPPL2 作为实体瘤 CAR 治疗的候选靶点,并探索 synNotch 组合抗原电路以降低 on-target/off-tumor 毒性风险。
局限性
- 证据来自小鼠模型,尚需临床研究验证 ALPPL2 靶向与 synNotch CAR 电路在人体的安全性和疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The first clinically approved engineered chimeric antigen receptor (CAR) T cell therapies are remarkably effective in a subset of hematological malignancies with few therapeutic options. Although these clinical successes have been exciting, CAR T cells have hit roadblocks in solid tumors that include the lack of highly tumor-specific antigens to target, opening up the possibility of life-threatening "on-target/off-tumor" toxicities, and problems with T cell entry into solid tumor and persistent activity in suppressive tumor microenvironments. Here, we improve the specificity and persistent antitumor activity of therapeutic T cells with synthetic Notch (synNotch) CAR circuits. We identify alkaline phosphatase placental-like 2 (ALPPL2) as a tumor-specific antigen expressed in a spectrum of solid tumors, including mesothelioma and ovarian cancer. ALPPL2 can act as a sole target for CAR therapy or be combined with tumor-associated antigens such as melanoma cell adhesion molecule (MCAM), mesothelin, or human epidermal growth factor receptor 2 (HER2) in synNotch CAR combinatorial antigen circuits. SynNotch CAR T cells display superior control of tumor burden when compared to T cells constitutively expressing a CAR targeting the same antigens in mouse models of human mesothelioma and ovarian cancer. This was achieved by preventing CAR-mediated tonic signaling through synNotch-controlled expression, allowing T cells to maintain a long-lived memory and non-exhausted phenotype. Collectively, we establish ALPPL2 as a clinically viable cell therapy target for multiple solid tumors and demonstrate the multifaceted therapeutic benefits of synNotch CAR T cells.
引用
- Hyrenius-Wittsten A, Su Y, Park M, et al. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med. 2021. PMID: 33910981. doi:10.1126/scitranslmed.abd8836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。